The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
about
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The CDK inhibitor AT7519M in p ...... Canadian Cancer Trials Group.
@en
The CDK inhibitor AT7519M in p ...... y chronic lymphocytic leukemia
@nl
type
label
The CDK inhibitor AT7519M in p ...... Canadian Cancer Trials Group.
@en
The CDK inhibitor AT7519M in p ...... y chronic lymphocytic leukemia
@nl
prefLabel
The CDK inhibitor AT7519M in p ...... Canadian Cancer Trials Group.
@en
The CDK inhibitor AT7519M in p ...... y chronic lymphocytic leukemia
@nl
P2093
P2860
P1433
P1476
The CDK inhibitor AT7519M in p ...... e Canadian Cancer Trials Group
@en
P2093
Graeme Fraser
Haji I Chalchal
Jean Powers
Joana Sederias
John F Lyons
John Kuruvilla
Lesley Seymour
Marcia Toguchi
Matthew D Seftel
P2860
P304
P356
10.1080/10428194.2016.1239259
P577
2016-10-17T00:00:00Z